Artificial Intelligence - Advisory or Adversary?

Competing Interests: Disclosure: RM reports: institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Arena, AstraZeneca, Baim Institute for Clinical Research, Beth Israel Deaconess, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, Cardiawave, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, CytoSorbents, DSI, Duke University, Element Science, Faraday, Humacyte, Idorsia, Insel Gruppe, Magenta, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, Pi-Cardia, RenalPro, Shockwave, Vivasure and Zoll; personal fees from Cine-Med Research and WebMD; consulting fees paid to the institution from Abbott, Janssen, Medtronic and Novartis; equity <1% in Applied Therapeutics, Elixir Medical, Stel Life and ControlRad (spouse); American Heart Association (Scientific Advisory Board member), American College of Cardiology (Board of Trustees member) and Society for Cardiovascular Angiography (Women in Innovations Committee member); Journal of the American Medical Association associate editor; faculty, Cardiovascular Research Foundation (no fee). All other authors have no conflicts of interest to declare.